This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Trevi Therapeutics (TRVI), Joint (JYNT) and ImmunityBio (IBRX)

Tipranks - Tipranks - Sat May 9, 8:12AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Trevi Therapeutics (TRVI), Joint (JYNT) and ImmunityBio (IBRX) with bullish sentiments.

Claim 55% Off TipRanks

Trevi Therapeutics (TRVI)

In a report released today, Leland Gershell from Oppenheimer reiterated a Buy rating on Trevi Therapeutics, with a price target of $24.00. The company’s shares closed last Thursday at $14.05.

According to TipRanks.com, Gershell is a 4-star analyst with an average return of 8.5% and a 39.9% success rate. Gershell covers the Healthcare sector, focusing on stocks such as Aardvark Therapeutics, Inc., Lexeo Therapeutics, Inc., and Capricor Therapeutics. ;'>

Currently, the analyst consensus on Trevi Therapeutics is a Strong Buy with an average price target of $24.50, representing a 72.3% upside. In a report issued on May 6, Needham also maintained a Buy rating on the stock with a $23.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Joint (JYNT)

Roth MKM analyst George Kelly reiterated a Buy rating on Joint today and set a price target of $12.00. The company’s shares closed last Thursday at $8.67.

According to TipRanks.com, Kelly is a 4-star analyst with an average return of 5.4% and a 45.6% success rate. Kelly covers the NA sector, focusing on stocks such as GEN Restaurant Group, Inc. Class A, Peloton Interactive, and Xponential Fitness. ;'>

Joint has an analyst consensus of Hold, with a price target consensus of $9.85.

ImmunityBio (IBRX)

In a report released today, Edward Tenthoff from Piper Sandler reiterated a Buy rating on ImmunityBio, with a price target of $12.00. The company’s shares closed last Thursday at $7.76.

According to TipRanks.com, Tenthoff is a 4-star analyst with an average return of 8.5% and a 42.0% success rate. Tenthoff covers the Healthcare sector, focusing on stocks such as CAMP4 Therapeutics Corporation, Acrivon Therapeutics, Inc., and Arrowhead Pharmaceuticals. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for ImmunityBio with a $13.00 average price target, representing a 66.3% upside. In a report issued on April 29, H.C. Wainwright also maintained a Buy rating on the stock with a $15.00 price target.

Read More on TRVI:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).